Douglas Klumpp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Douglas Klumpp has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- B. Frank Gupton
Virginia Commonwealth University
6 shared publications - Saeed Ahmad
Virginia Commonwealth University
6 shared publications - Justina Burns
M4ALL VCU
5 shared publications - Limei Jin
Virginia Commonwealth University
5 shared publications - George Laidlaw
M4ALL VCU
4 shared publications - Aline Nunes De Souza
Virginia Commonwealth University
2 shared publications
Latest Publications
- Open Access
- 12 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Development of a scalable synthetic route to (1R,5R)-2,2-dimethoxybicyclo[3.1.0]hexan-3-one: an important intermediate in the synthesis of lenacapavir
(1R,5R)-2,2-Dimethoxybicyclo[3.1.0]hexan-3-one is used in the asymmetric synthesis of lenacapavir. Herein, we report an enantioselective synthesis of this important chiral intermediate from the inexpensive commodity (R)-epichlorohydrin. This synthetic method comprises 6 steps, including a 4-step telescoped bicyclic ketone synthesis, I2-promoted hydroxylation, and an Albright-Goldman oxidation. This sequence affords (1R,5R)-2,2-dimethoxybicyclo[3.1.0]hexan-3-one in an overall 25% isolated yield as an enantiomerically pure compound. The entire process has been successfully demonstrated on a hundred-gram scale.
- 12 December 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment of a scalable synthetic route to (1R,5R)-2,2-dimethoxybicyclo[3.1.0]hexan-3-one: an important intermediate in the synthesis of lenacapavir
(1R,5R)-2,2-Dimethoxybicyclo[3.1.0]hexan-3-one is used in the asymmetric synthesis of lenacapavir. Herein, we report an enantioselective synthesis of this important chiral intermediate from the inexpensive commodity (R)-epichlorohydrin. This synthetic method comprises 6 steps, including a 4-step telescoped bicyclic ketone synthesis, I2-promoted hydroxylation, and an Albright-Goldman oxidation. This sequence affords (1R,5R)-2,2-dimethoxybicyclo[3.1.0]hexan-3-one in an overall 25% isolated yield as an enantiomerically pure compound. The entire process has been successfully demonstrated on a hundred-gram scale.
- Open Access
Practical Synthesis of 7-Bromo-4-chloro-1H-indazol-3-amine: An Important Intermediate to Lenacapavir
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections. In this manuscript, we describe a new approach to synthesizing 7-bromo-4-chloro-1H-indazol-3-amine from inexpensive 2,6-dichlorobenzonitrile. This synthetic method utilizes a two-step sequence including regioselective bromination and heterocycle formation with hydrazine to give the desired product in an overall isolated yield of 38–45%. The new protocol has been successfully demonstrated on hundred-gram scales without the need for column chromatography purification. This new synthesis provides a potential economical route to the large-scale production of this heterocyclic fragment of Lenacapavir.
Open AccessPractical Synthesis of 7-Bromo-4-chloro-1H-indazol-3-amine: An Important Intermediate to Lenacapavir
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections. In this manuscript, we describe a new approach to synthesizing 7-bromo-4-chloro-1H-indazol-3-amine from inexpensive 2,6-dichlorobenzonitrile. This synthetic method utilizes a two-step sequence including regioselective bromination and heterocycle formation with hydrazine to give the desired product in an overall isolated yield of 38–45%. The new protocol has been successfully demonstrated on hundred-gram scales without the need for column chromatography purification. This new synthesis provides a potential economical route to the large-scale production of this heterocyclic fragment of Lenacapavir.
- Open Access
- 8 May 2024
- Published by American Chemical Society (ACS) in ChemRxiv
A new synthesis of the amine fragment: an important intermediate to the anti-HIV drug lenacapavir
Herein, we describe a new five-step approach to prepare 1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethan-1-amine, an important intermediate in the synthesis of lenacapavir. The key step in the sequence is the Weinreb amide-based ketone synthesis, which provides an alternative entry point to the core structural component. Starting from the inexpensive 2-(3,5-difluorophenyl)acetic acid, the Weinreb amide synthesis and the followed nucleophilic substitution afford the ketone in 47% yield. The subsequent functional group manipulation delivers the racemic amine which can be resolved with known mandelic acid resolution. This synthetic route has been demonstrated on decagram scale and affords the racemic amine in an overall isolated yield of 25%.
- 8 May 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessA new synthesis of the amine fragment: an important intermediate to the anti-HIV drug lenacapavir
Herein, we describe a new five-step approach to prepare 1-(3,6-dibromopyridin-2-yl)-2-(3,5-difluorophenyl)ethan-1-amine, an important intermediate in the synthesis of lenacapavir. The key step in the sequence is the Weinreb amide-based ketone synthesis, which provides an alternative entry point to the core structural component. Starting from the inexpensive 2-(3,5-difluorophenyl)acetic acid, the Weinreb amide synthesis and the followed nucleophilic substitution afford the ketone in 47% yield. The subsequent functional group manipulation delivers the racemic amine which can be resolved with known mandelic acid resolution. This synthetic route has been demonstrated on decagram scale and affords the racemic amine in an overall isolated yield of 25%.
- Open Access
- 30 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Synthetic process development of (R)-(+)-1,2-epoxy-5-hexene: an important chiral building block
Herein, we describe two practical approaches to synthesize (R)-(+)-1,2-epoxy-5-hexene from inexpensive and readily available raw materials and reagents. The first approach is a two-step sequence, involving an epoxidation with meta-chloroperoxybenzoic acid (mCPBA) and a chiral resolution with (salen)Co(II), producing (R)-(+)-1,2-epoxy-5-hexene in 24-30% of overall yield. The second approach utilizes the readily available (R)-epichlorohydrin as the starting material and features an epoxide ring opening reaction with allylMgCl and the NaOH mediated ring closure reaction. Development of this two-step process affords R-(+)-1,2-epoxy-5-hexene in overall isolated yields of 55-60% with an exceptional purity profile. Both approaches have been successfully demonstrated on 100-200g scales.
- 30 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessSynthetic process development of (R)-(+)-1,2-epoxy-5-hexene: an important chiral building block
Herein, we describe two practical approaches to synthesize (R)-(+)-1,2-epoxy-5-hexene from inexpensive and readily available raw materials and reagents. The first approach is a two-step sequence, involving an epoxidation with meta-chloroperoxybenzoic acid (mCPBA) and a chiral resolution with (salen)Co(II), producing (R)-(+)-1,2-epoxy-5-hexene in 24-30% of overall yield. The second approach utilizes the readily available (R)-epichlorohydrin as the starting material and features an epoxide ring opening reaction with allylMgCl and the NaOH mediated ring closure reaction. Development of this two-step process affords R-(+)-1,2-epoxy-5-hexene in overall isolated yields of 55-60% with an exceptional purity profile. Both approaches have been successfully demonstrated on 100-200g scales.
- Open Access
- 30 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Practical synthesis of 7-bromo-4-chloro-1H-indazol-3-amine: an important intermediate to Lenacapavir
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections. In this manuscript, we describe a new approach to synthesizing 7-bromo-4-chloro-1H-indazol-3-amine from inexpensive 2,6-dichlorobenzonitrile. This synthetic method utilizes a two-step sequence including a regioselective bromination and heterocycle formation with hydrazine to give the desired product in an overall isolated yield of 38-45%. The new protocol has been successfully demonstrated on hundred-gram scales without the need of column chromatography purifications. This new synthesis provides a potential economical route to large scale production of this heterocyclic fragment of Lenacapavir.
- 30 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPractical synthesis of 7-bromo-4-chloro-1H-indazol-3-amine: an important intermediate to Lenacapavir
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections. In this manuscript, we describe a new approach to synthesizing 7-bromo-4-chloro-1H-indazol-3-amine from inexpensive 2,6-dichlorobenzonitrile. This synthetic method utilizes a two-step sequence including a regioselective bromination and heterocycle formation with hydrazine to give the desired product in an overall isolated yield of 38-45%. The new protocol has been successfully demonstrated on hundred-gram scales without the need of column chromatography purifications. This new synthesis provides a potential economical route to large scale production of this heterocyclic fragment of Lenacapavir.
- Open Access
- 24 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
High Yielding, Multigram-Scale Synthesis of TBAJ-876 Fragment, 876A-B
TBAJ-876 is an anti-tuberculosis drug shown to have high activity against multi-drug resistant tuberculosis (TB). We report a very efficient synthesis of the TBAJ-876 fragment 876A-B using an aldol condensation strategy starting from 6-bromo-3,4-dihydroquinolin-2(H)-one. The synthesis has been accomplished at multigram scale without the need of chromatography purification steps.
- 24 April 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessHigh Yielding, Multigram-Scale Synthesis of TBAJ-876 Fragment, 876A-B
TBAJ-876 is an anti-tuberculosis drug shown to have high activity against multi-drug resistant tuberculosis (TB). We report a very efficient synthesis of the TBAJ-876 fragment 876A-B using an aldol condensation strategy starting from 6-bromo-3,4-dihydroquinolin-2(H)-one. The synthesis has been accomplished at multigram scale without the need of chromatography purification steps.